Ampliprep cobas taqman hiv 1 test v 2

Samples from 9 HIV-uninfected subjects, 19 subjects on suppressive ART, and 9 viremic individuals not receiving ART at the time of sampling were used in this study. None of the participants under ART had detectable plasma viremia at the time of the study, as assessed by viral load measurements using AmpliPrep/Cobas TaqMan HIV-1 test v 2.0 (Roche), with a detection limit of 20 HIV RNA copies/ml of plasma. All participants underwent lymph node biopsy (inguinal lymph nodes), and blood was collected at the same time. Subject characteristics are summarized in Table 1. These studies were approved by the Institutional Review Board of the Centre Hospitalier Universitaire Vaudois, and all subjects gave written informed consent.

This was a prospective diagnostic accuracy study. Each study participant provided 12 ml of venous blood collected in EDTA tubes for the preparation of fresh plasma, DBS, and FDPS samples. Three VL tests were carried out for each participant, and clinical decisions were based on the results of VL tests carried out on fresh plasma as part of the standard of care. HIV-1 RNA VLs were measured using the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, v2.0 (CAP/CTM), system, one of the most commonly used HIV VL testing platforms in low- and middle-income countries (12 ) with acceptable accuracy (13 (link)).